Invention Grant
- Patent Title: Extended release pharmaceutical formulations with controlled impurity levels
-
Application No.: US15633338Application Date: 2017-06-26
-
Publication No.: US10010529B2Publication Date: 2018-07-03
- Inventor: Joseph A. Fix , Shirish A. Shah , Pratibha S. Pilgaonkar , Anilkumar S. Gandhi
- Applicant: Ezra Pharma LLC , Rubicon Research Private Limited
- Applicant Address: US AR Little Rock IN Mumbai
- Assignee: Ezra Pharma LLC,Rubicon Research Private Limited
- Current Assignee: Ezra Pharma LLC,Rubicon Research Private Limited
- Current Assignee Address: US AR Little Rock IN Mumbai
- Agency: Amin Talati Upadhye LLP
- Agent Adam D. Sussman; George M. Carrera, Jr.
- Main IPC: A61K31/41
- IPC: A61K31/41 ; A61K9/00 ; A61K9/24 ; A61K9/28
Abstract:
The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.
Public/Granted literature
- US20170290805A1 EXTENDED RELEASE PHARMACEUTICAL FORMULATIONS WITH CONTROLLED IMPURITY LEVELS Public/Granted day:2017-10-12
Information query
